Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Chiasson and colleagues1 claimed to have found an effect of acarbose on
the risk of cardiovascular events in patients with IGT. These results are
based on the evaluation of the so-called "modified" intent-to-treat (ITT)
population, which excluded 61 originally randomized patients, most for lack
of valid postrandomization data. It would be of interest to know how many
cardiac events occurred in this entire cohort. However, outcome information
about the original study group consisting of 714 patients in the acarbose
group and 715 in the placebo group was previously available as "safety data"
on the trial sponsor's study Web site and is now available at http://www.di-em.de/data/STOPNIDDM_table1.pdf. According to these data, cardiovascular events were similarly distributed
between the original intervention and control group: in total 33 and 39 patients
had at least one event.
Kaiser T, Sawicki PT. Acarbose for Patients With Hypertension and Impaired Glucose ToleranceAcarbose for Patients With Hypertension and Impaired Glucose Tolerance. JAMA. 2003;290(23):3066. doi:10.1001/jama.290.23.3066-a